Ticagrelor contraindications: Difference between revisions
Gerald Chi (talk | contribs) mNo edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| Line 7: | Line 7: | ||
====History of Intracranial Hemorrhage==== | ====History of Intracranial Hemorrhage==== | ||
BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage | BRILINTA is contraindicated in patients with a history of [[intracranial hemorrhage|intracranial hemorrhage (ICH)]] because of a high risk of recurrent [[ICH]] in this population ''[see [[Ticagrelor clinical studies|Clinical Studies]]]''. | ||
====Active Bleeding==== | ====Active Bleeding==== | ||
Revision as of 22:52, 11 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Jesus Rosario Hernandez, M.D. [2]
Contraindications
History of Intracranial Hemorrhage
BRILINTA is contraindicated in patients with a history of intracranial hemorrhage (ICH) because of a high risk of recurrent ICH in this population [see Clinical Studies].
Active Bleeding
BRILINTA is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage [see Warnings and Precautions (5.1) and Adverse Reactions (6.1)].
Severe Hepatic Impairment
BRILINTA is contraindicated in patients with severe hepatic impairment because of a probable increase in exposure, and it has not been studied in these patients. Severe hepatic impairment increases the risk of bleeding because of reduced synthesis of coagulation proteins [see Clinical Pharmacology (12.3)].
Hypersensitivity
BRILINTA is contraindicated in patients with hypersensitivity (e.g. angioedema) to ticagrelor or any component of the product [see Adverse Reactions (6.2)].[1]